C-Abl-p38α signaling plays an important role in MPTP-induced neuronal death

Cell Death and Differentiation

Volumn 23, Issue 3, 2016, Pages 542-552

  Wu, R ^a,b   Chen, H ^a,c   Ma, J ^a,b   He, Q ^a,b   Huang, Q ^d   Liu, Q ^b   Li, M ^d   Yuan, Z ^a,b,c  

^a INSTITUTE OF BIOPHYSICS   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ABELSON KINASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DEATH; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; MOLECULAR GENETICS; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMINO ACID SEQUENCE; ANIMALS; CELL DEATH; DOPAMINERGIC NEURONS; ENZYME ACTIVATION; FEMALE; HEK293 CELLS; HUMANS; IMATINIB MESYLATE; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR SEQUENCE DATA; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-ABL; SIGNAL TRANSDUCTION;

EID: 84957566137     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.135     Document Type: Article

References (32)

1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744-1754.
2. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Exp Rev Mol Med 2009; 11: e22.
3. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
4. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
5. Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 2008; 100: 617-631.
6. Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y et al. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci 2011; 31: 9611-9619.
7. Liu W, Wu J, Xiao L, Bai Y, Qu A, Zheng Z et al. Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. PLoS One 2012; 7: e36562.
8. Cancino GI, Perez de Arce K, Castro PU, Toledo EM, von Bernhardi R, Alvarez AR. c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice. Neurobiol Aging 2011; 32: 1249-1261.
9. Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci USA 2010; 107: 16691-16696.
10. Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J Neurosci 2011; 31: 157-163.
11. Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S et al. c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alphasynuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet 2014; 23: 2858-2879.
12. Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet 2013; 22: 3315-3328.
13. Imam SZ, Trickler W, Kimura S, Binienda ZK, Paule MG, Slikker W Jr et al. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One 2013; 8: e65129.
14. Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci Rep 2014; 4: 4874.
15. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085-1092.
16. Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S et al. c-Abl phosphorylates alpha-syn and regulates its degradation, implication for alpha-syn clearance and contribution to the pathogenesis of Parkinson's Disease. Hum Mol Genet 2014; 23: 2858-2879.
17. Cao C, Leng Y, Li C, Kufe D. Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response. J Biol Chem 2003; 278: 12961-12967.
18. Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol 1995; 23: 1153-1159.
19. Sanguinetti AR, Mastick CC. c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cell Signal 2003; 15: 289-298.
20. Burton EA, Oliver TN, Pendergast AM. Abl kinases regulate actin comet tail elongation via an N-WASP-dependent pathway. Mol Cell Biol 2005; 25: 8834-8843.
21. Rothweiler U, Aberg E, Johnson KA, Hansen TE, Jorgensen JB, Engh RA. p38alpha MAP kinase dimers with swapped activation segments and a novel catalytic loop conformation. J Mol Biol 2011; 411: 474-485.
22. Casanova E, Fehsenfeld S, Mantamadiotis T, Lemberger T, Greiner E, Stewart AF et al. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 2001; 31: 37-42.
23. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998; 39: 167-180.
24. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 33-44.
25. Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000; 28: 551-557.
26. Schlatterer SD, Acker CM, Davies P. c-Abl in neurodegenerative disease. J Mol Neurosci 2011; 45: 445-452.
27. Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC, DeAizpurua HJ. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 2000; 19: 4290-4297.
28. Bi W, Xiao L, Jia Y, Wu J, Xie Q, Ren J et al. c-Jun N-terminal kinase enhances MST1-mediated pro-apoptotic signaling through phosphorylation at serine 82. J Biol Chem 2010; 285: 6259-6264.
29. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005; 15: 11-18.
30. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998; 273: 1741-1748.
31. Mittelstadt PR, Yamaguchi H, Appella E, Ashwell JD. T cell receptor-mediated activation of p38{alpha} by mono-phosphorylation of the activation loop results in altered substrate specificity. J Biol Chem 2009; 284: 15469-15474.
32. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2: 141-151.